ARTIA-Lung
Phase NA Withdrawn
BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases
Phase 2 Withdrawn
Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression
Phase 2 Withdrawn
Effect of N-Acetyl Cysteine (NAC) on the Oral Microbiome
Phase 2 Withdrawn
Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
Phase 2 Withdrawn
CRATER
Phase 2 Withdrawn
A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis(SHR-1210-HLJ-009)
Phase NA Withdrawn
CKPancreas
Phase 2 Withdrawn
Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers
Phase 2/3 Withdrawn
ADHERE
Phase 3 Withdrawn
Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer
Phase 2 Withdrawn
OLIVER
Phase NA Withdrawn
Proton Therapy for High Risk Prostate Cancer
Phase NA Withdrawn
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Phase 3 Withdrawn
Z0011-China
Phase 3 Withdrawn
DIACAL
Phase 2 Withdrawn
Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
Phase 2 Withdrawn
NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer
Phase 2 Withdrawn
Prometheus
Phase 4 Withdrawn
The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer
Phase 2 Withdrawn
Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
Phase 2 Withdrawn
Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer
Phase 1 Withdrawn
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment
Phase 1 Withdrawn
CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)
Phase 2 Withdrawn
S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer
Phase 2 Withdrawn
Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1 Withdrawn
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
Phase 2 Withdrawn
High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma
Phase 2 Withdrawn
Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma
Phase 2 Withdrawn
Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia
Phase 1/2 Withdrawn
Chemotherapy and Hormone Therapy as First-Line Therapy in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer
Phase 3 Withdrawn
Liposomal Tretinoin in Treating Patients With Recurrent or Refractory Hodgkin's Disease
Phase 2 Withdrawn